Corpus Intelligence IC Memo — GEISINGER BLOOMSBURG HOSPITAL 2026-04-26 04:04 UTC
IC Memo — GEISINGER BLOOMSBURG HOSPITAL
Investment Committee Memorandum | PA | 40 beds | Grade C | EBITDA uplift $5.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

GEISINGER BLOOMSBURG HOSPITAL

CCN 390003 | COLUMBIA, PA | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

GEISINGER BLOOMSBURG HOSPITAL is a 40-bed suburban community hospital in COLUMBIA, PA with $75.3M in net patient revenue and a 6.5% operating margin. The hospital serves a payer mix of 25.4% Medicare, 2.1% Medicaid, and 72.6% commercial.

Thesis: Turnaround. Our ML models identify $5.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 6.5% to 13.8% (+736bps).

Net Revenue HCRIS$75.3M
Current EBITDA COMPUTED$4.9M
Operating Margin COMPUTED6.5%
Occupancy HCRIS55.2%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS16.4%
Distress Probability ML43.6%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
81
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 6.5% places it above the state median. Among 81 size-comparable peers (20-80 beds), the median margin is 1.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 81 hospitals in the comp set.

HospitalStateBedsRevenueMargin
GEISINGER BLOOMSBURG HOSPITAL (Target)PA40$75.3M6.5%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
UPMC HANOVERPA73$200.8M18.2%
MEMORIAL HOSPITALPA80$184.5M13.1%
UPMC CARLISLEPA72$165.0M19.5%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
MINERS MEMORIAL MEDICAL CENTERPA49$107.7M12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$916K+122bp9mo
Clean Claim Rate88.0%96.0%$48K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$916K
Clean Claim Rate
$48K
Total EBITDA Uplift$5.5M
Current EBITDA$4.9M
+ RCM Uplift+$5.5M
Pro Forma EBITDA$10.4M
Current Margin6.5%
Pro Forma Margin13.8%
WC Released (1x)$2.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$7.5M$87.5M11.70x63.5%
Base (11x exit)10.0x11.0x$7.5M$98.7M13.20x67.5%
Bull Case9.0x11.0x$6.7M$119.4M17.74x77.8%
Bull (12x exit)9.0x12.0x$6.7M$132.2M19.65x81.4%
Bear Case11.0x10.0x$8.2M$57.3M6.97x47.5%
Bear (11x exit)11.0x11.0x$8.2M$65.8M8.00x51.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 81 hospitals with 20-80 beds
  • Same-state prioritization (n=82)
  • Comp margins: P25=-12.8% / P50=1.4% / P75=9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.